Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Medscape4d
Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Monthly Prescribing Reference4d
Semaglutide Improves Walking Ability in T2D Patients With Peripheral Artery Disease
Additionally, the trial met all secondary endpoints, demonstrating significant improvement with semaglutide vs placebo in pain-free walking distance (ETR: 1.11 [95% CI, 1.03-1.20; P =.0046 ...
Healio5d
Ozempic boosts walking distance for patients with diabetes, peripheral artery disease
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
Medical Dialogues1d
Semaglutide Boosts Walking Capacity in PAD and Type 2 Diabetes, STRIDE Trial Finds
USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...
PharmiWeb5d
CPC Announces Semaglutide Significantly Improves Walking Distance, Symptoms and Quality of Life for People with PAD and Diabetes
Study underscores the direct vascular effects of this class of drugs, researchers say AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) ...
Hosted on MSN5d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
This between-group difference produced an estimated treatment ratio of 1.13 for semaglutide (95% CI 1.06-1.21), corresponding ...
Yahoo Finance3d
ACC 25: semaglutide improves function in PAD patients with T2D in STRIDE study
Semaglutide statistically significantly improved maximum walking distance in patients - the main parameter to assess functional PAD improvement: 40 metres of difference being walked by the ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
ACC 25: semaglutide improves function in PAD patients with T2D in STRIDE study
PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...